ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of “Buy” by Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given an average rating of “Buy” by the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $77.71.

ANIP has been the topic of several recent research reports. Leerink Partners began coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective on the stock. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Finally, Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th.

ANI Pharmaceuticals Stock Up 0.3 %

Shares of ANIP opened at $55.44 on Friday. The firm has a market cap of $1.17 billion, a P/E ratio of -100.80 and a beta of 0.73. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81. The firm’s 50-day simple moving average is $57.01 and its 200 day simple moving average is $59.36.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.05 earnings per share. On average, analysts forecast that ANI Pharmaceuticals will post 3.87 earnings per share for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,231 shares of company stock worth $2,434,286. Corporate insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Innealta Capital LLC acquired a new position in shares of ANI Pharmaceuticals during the second quarter worth $65,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after purchasing an additional 579 shares in the last quarter. XTX Topco Ltd bought a new position in ANI Pharmaceuticals in the second quarter valued at about $207,000. Profund Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals during the second quarter valued at about $225,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of ANI Pharmaceuticals during the second quarter valued at about $228,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.